GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES THE EUROPEAN COMMISSION''S APPROVAL OF CARVYKTI FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
GENSCRIPT BIO: FORM OF PROXY FOR 2024 ANNUAL GENERAL MEETING
GENSCRIPT BIO: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES PRELIMINARY SALES FOR CARVYKTI FOR THE QUARTER ENDED 31 MARCH 2024
GENSCRIPT BIO: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES AND ADOPTION OF THE AMENDED MEMORANDUM AND ARTICLES
GENSCRIPT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
GENSCRIPT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEE
GENSCRIPT BIO: Nomination Committee -Terms of Reference
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES THE U.S. FDA''S APPROVAL OF CARVYKTI FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
GENSCRIPT BIO: Next Day Disclosure Return
GENSCRIPT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH USA INC. ENTERS INTO MASTER MANUFACTURING AND SUPPLY SERVICES AGREEMENT WITH NOVARTIS PHARMACEUTICALS CORPORATION
GENSCRIPT BIO: Next Day Disclosure Return
GENSCRIPT BIO: VOLUNTARY ANNOUNCEMENT: LEGEND BIOTECH ANNOUNCES PUBLICATION OF INAUGURAL ESG REPORT
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 OF A LISTED SUBSIDIARY - LEGEND BIOTECH CORPORATION
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION ANNOUNCES POSITIVE OPINION FROM THE U.S. FDA ODAC FOR CARVYKTI FOR THE EARLIER TREATMENT OF PATIENT WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
GENSCRIPT BIO: OVERSEAS REGULATORY ANNOUNCEMENT: LEGEND BIOTECH CORPORATION RELEASES SPONSOR AND FDA BRIEFING BOOKS FOR CARVYKTI
GENSCRIPT BIO: Risk Management and ESG Committee - Terms of Reference
GENSCRIPT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
GENSCRIPT BIO: Notification Letter to Non-Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
No Data